



Form PTO-1449	ATTY. DOCKET NO. 0283-0192PUS1	APPLICATION NO. 10/827,294
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)	APPLICANT KUBO, Akira et al.	
	FILING DATE April 20, 2004	GROUP Unassigned-1624

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
DR	US 4,532,250	A	1985-07-30	Stout et al.	----	----	
DR	US 3,538,104		1970-11-03	Gruenfeld, N.	----	----	
DR	US 6,329,526	B1	2001-12-11	Adams et al.	----	----	
DR	US 6,677,337	B2	2004-01-13	Laufersweiler et al.	----	----	
DR	US 6,566,357	B1	2003-05-20	Laufersweiler et al.	----	----	
DR	US 6,730,668	B2	2004-05-04	Clark et al.	----	----	
DR	US 2003/0105084	A1	2003-06-05	Clark et al.	----	----	
DR	US 6,579,874	B2	2003-06-17	Revesz et al.	----	----	
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
DR	JPO	10-291982	A	1998-04-11	JAPAN	----	----	X	
DR	EP	1205478	A1	2002-05-15	EPO	----	----		
DR	EP	1180518	A1	2002-02-20	EPO	----	----		

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

DR	Robert W. Carling, et al., "1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D <sub>4</sub> Receptor with Excellent Selectivity over Ion Channels", <i>J. Med. Chem.</i> 1999, 42, 2706-2715.
DR	Winton D. Jones, Jr., et al., "The Synthesis and Biological Activity of Pyridyl-2(3H)-Oxazolones", <i>Proceedings: NOBCCHe '94</i> , volume 21, August 1994., 100-115.
DR	Jeffrey C. Boehm & Jerry L. Adams, "Expert Opinion on Therapeutic Patents, "New inhibitors of p38 kinase", <i>Ashley Publications Ltd.</i> , ISSN 1354-3776 (2000), 25-37.
DR	Stephen E. deLaszlo et al., "Pyrroles and Other Heterocycles as Inhibitors of P38 Kinase", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 8 (1998) 2689-2694.

EXAMINER  /Deepak Rao/	DATE CONSIDERED 02/27/2007
------------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.S.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

0283-0192PUS1

APPLICATION NO.

10/827,294

APPLICANT

KUBO, Akira et al.

FILING DATE

April 20, 2004

GROUP

1625- 1624

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
DR	WO	WO 02/076974	A2	2002-10-03	WIPO	---	---		

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)


EXAMINER

/Deepak Rao/

DATE CONSIDERED

02/27/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.S.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.